Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | PARL | Q9H300 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927442 | 0.87 | GAA (0.49) | HTR6HTTALDH1A1LMNAHPGD | |
| SCHEMBL10768316 | 0.83 | CXCL8 (0.50) | HTR6MEN1HTTKMT2AALDH1A1 | |
| SCHEMBL28775093 | 0.81 | PPARG (0.48) | HTR6MEN1HTTKMT2AALDH1A1 | |
| SCHEMBL28927540 | 0.81 | MEN1 (0.39) | HTR6MEN1HTTKMT2AALDH1A1 | |
| SCHEMBL3624022 | 0.77 | CA1 (0.42) | HTR6MEN1HTTKMT2ACA2 | |
| SCHEMBL28410334 | 0.75 | HTR6 (0.34) | HTR6MEN1HTTKMT2AALDH1A1 | |
| SCHEMBL1642678 | 0.68 | DAO (0.39) | HTR6MEN1HTTKMT2AALDH1A1 | |
| SCHEMBL29558135 | 0.67 | HTR6 (1.00) | HTR6MEN1HTTKMT2AALDH1A1 | |
| SCHEMBL429849 | 0.67 | HTR6 (1.00) | HTR6MEN1HTTKMT2AALDH1A1 | |
| SCHEMBL10291046 | 0.67 | CA12 (0.55) | HTR6MEN1HTTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104114169-A | Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis | ATOPIX THERAPEUTICS LTD | 2014-10-22 | — | — | CN | claimed |
| EP-2325186-B1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS LLC (US) | 2014-10-08 | — | — | EP | claimed |
| US-8796455-B2 | Fused bicyclic mTOR inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-08-05 | — | — | US | claimed |
| US-8586546-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-11-19 | — | — | US | claimed |
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI Pharmaceuticals, LLC | 2013-06-27 | — | — | US | claimed |
| US-8314111-B2 | Fused bicyclic motor inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-11-20 | — | — | US | claimed |
| US-20120207767-A1 | Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors | OSI PHARMACEUTICALS, LLC. | 2012-08-16 | — | — | US | claimed |
| EP-2459191-A1 | MTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY | OSI Pharmaceuticals, LLC (US) | 2012-06-06 | — | — | EP | claimed |
| US-8114846-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-02-14 | — | — | US | claimed |
| US-20110218183-A1 | Fused Bicyclic mTOR Inhibitors | OSI Pharmaceuticals, LLC | 2011-09-08 | — | — | US | claimed |
| EP-2325186-A2 | Fused Bicyclic mTor Inhibitors | OSI Pharmaceuticals, Inc. (US) | 2011-05-25 | — | — | EP | claimed |
| US-7943767-B2 | Fused bicyclic mTOR inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | claimed |
| EP-1951724-B1 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARM INC (US) | 2011-04-27 | — | — | EP | claimed |
| WO-2011014726-A1 | MTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY | OSI PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | WO | claimed |
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | claimed |
| US-20100099679-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARMACEUTICALS, INC. | 2010-04-22 | — | — | US | claimed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | claimed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | claimed |
| WO-2020036386-A1 | ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | 한국화학연구원 | 2020-02-20 | — | — | WO | disclosed |
| US-5488064-A | ANTIDIABETIC AGENTS, GASTROINTESTINAL AGENTS, ADRENERGIC BLOCKING AGENTS OR STIMULANTS AND TREATMENT OF OBESITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | HTR6 4695/4885MEN1 1845/4885HTT 3049/4885 |
| US-20120207767-A1 | Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors | EGFR, ERBB2, MTOR | HTR6 4056/4885MEN1 3291/4885HTT 2980/4885 |
| US-20100099679-A1 | FUSED BICYCLIC mTOR INHIBITORS | MTOR, RICTOR, MAPKAP1 | HTR6 4695/4885MEN1 1845/4885HTT 3049/4885 |
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | MTOR, RICTOR, MAPKAP1 | HTR6 4695/4885MEN1 1845/4885HTT 3049/4885 |
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | EGFR, ERBB2, RICTOR | HTR6 3393/4885MEN1 3248/4885HTT 2365/4885 |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | MTOR, MAPKAP1, RPS6KA1 | HTR6 4150/4885MEN1 1152/4885HTT 2710/4885 |
| US-20110218183-A1 | Fused Bicyclic mTOR Inhibitors | MTOR, RICTOR, MAPKAP1 | HTR6 4695/4885MEN1 1845/4885HTT 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.